Amgen Is Working On a Wegovy Competitor -- What It Means for Investors

The biotech's pipeline extends far beyond this exciting weight-loss product.It's a race to the riches in the anti-obesity drug market. This therapeutic area is projected to grow exponentially in the coming years. Novo Nordisk is one of the clear market leaders -- for now -- thanks to its now-famous therapy, Wegovy. However, several companies have promising pipeline candidates they hope will eventually challenge Wegovy.One of them is Amgen (AMGN -0.87%), one of the largest biotechs in the world. Amgen recent ...